Personalized Medicine  (Powerpoint presentation at the 1st Annual Translational Medicine Partnership Summit China ) New Markets in china : High opportunities for french SME (in French) 1st Annual Translational Medicine Partnership Summit China The New Chinese Markets China Bio Partnering Forum 2014 The SME Forum France – China The China Healthcare Investment Conference China's top priorities for 2014 Develop […]

Biopharmaceutical NewsWeek # 4       Acquisitions /mergers/joint-ventures May 19, 2014  Pfizer increases its offer for AstraZeneca. “They can either accept it or reject it” says Pfizer CEO Ian Read. This “final offer” values AstraZeneca at about $120 Billion, increases the cash component of the deal to +45% of the total price and values […]

Are big biotech companies better dealmakers than their pharmaceutical cousins? This was a question up for debate at a meeting of BioEurope in Turin, Italy in March 2014. Weighing in on the side of biotech, John McDonald of Biogen Idec observed that:   [quote style=”1″]Large pharmaceutical companies have shown “zero creativity” in their deal-making. [/quote]   […]

Biopharmaceutical News #3     Acquisitions Mergers Joint-ventures May 13, 2014 Shire has agreed to acquire San-Diego based biopharmaceutical company Lumena Pharmaceuticals for $260 million upfront plus an undisclosed net cash on success fees. The deal will reinforce Shire portfolio in rare-diseases and give them access for rare liver diseases.   Eurofins Scientific, a French-based […]

Biopharmaceutical News # 2 April 30, 2014  GSK reported pharmaceutical and vaccines turnover in the USA was down 10% to £1.13 billion, as sales across of Advair (salmeterol and fluticasone) for asthma and chronic obstructive pulmonary disease, fell 30% to £455 million. Also the launch of its new COPD drug Breo (fluticasone furoate/vilanterol) has been […]